Congratulations to another piece of fanatic work by the Moorfields team which was presented at the ARVO conference in Utah. In this presentation, we looked at real world outcomes of Faricimab antivegf injections over 2 years for wet AMD.
Faricimab, or Vabysmo is a monoclonal antibody used in the treatment of wet AMD. It is a bispecific monoclonal antibody that works by targeting vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2) target thereby stabilising the blood vessels of the retina.
Clinical trials have shown that Faricimab allows extension of patients up to 16 weeks with a large proportion of patients reaching the 16 week extension period. Clinical trials are usually conducted in a strict environment and these days real world data adds pivotal information about treatment outcomes in a real world environment with numerous confounding factors.
Our research looked at 172 patients newly diagnosed with wet AMD and treated with Faricimab and the mean number of injections was 7.6 in the first year and 4.2 in the second with significant visual improvement of 4.8 letters (or one line of the snellen chart) at the end of year 2.
The encouraging results confirm that patients maintain stability of disease with less treatment burden with Vabysmo in 2 years.
